Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The Job of Attorneys: It is Important to Comprehend When Legitimate Help - 2Was This Driver Simply Having Some good times Or Behaving Like An Ass?
- 312 times rockets and spacecraft crashed and burned in 2025
- 4Will your baby get a hep B vaccine? What RFK panel's ruling means.
- 5ByHeart infant formula recall tied to botulism outbreak puts parents on edge
- From Novice to Master: Dominating a Side interest
- Day to day Temporary Positions That Compensate Fairly in the US
- Get away from the Tedious Drudgery: Go into Business Today!
- The Electric Bicycle Americans Can Confide in 2024
- Who is behind Al-Majd, the Israeli-linked evacuation group sending Gazans to South Africa?
- First SpaceX booster for upgraded Starship fails during test in Texas
- 5 VIPs That Changed Style
- The most effective method to Settle on Informed Conclusions about Senior Insuranc.
- Artemis 2 moon rocket gets 'America 250' paint job | Space photo of the day for Dec. 23, 2025
